Genio System 2.1
Nyxoah S.A. · Decision date Aug 8, 2025
What did the FDA approve?
FDA records P240024 as an original PMA application. The recorded decision is approval, dated Aug 8, 2025.
FDA approval order statement
Approval for The Nyxoah Genio System 2.1, which includes the Implantable Stimulator Model #2954, Surgical Template, External Stimulator, Disposable Patch, Activation Chip Model #2364, Charging Unit Model #2238, Sleep Lab Application, Repeater, and Smartphone Application. It is indicated for use in the treatment of moderate to severe Obstructive Sleep Apnea (OSA) (apnea-hypopnea index [AHI] of greater than or equal to 15 and less than or equal to 65). The device is intended for adult patients 22 years of age and older who have been confirmed to fail, cannot tolerate or are ineligible to be treated with current standard of care treatments including lifestyle modifications, positive airway pressure (PAP) treatments (such as continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BiPAP] machines), oral appliances (such as mandibular advancement devices), and pharmacotherapy (such as tirzepatide). PAP failure is defined as an inability to eliminate OSA (residual AHI of greater than 15 despite PAP usage), and PAP intolerance is defined as: 1. Inability to use PAP (at least 5 nights per week of usage; usage defined as greater than 4 hours of use per night), or 2. Unwillingness to use PAP (PAP therapy initiated and subsequently discontinued by choice).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Anesthesiology
- Decision date
- Aug 8, 2025
Regulatory record facts
- Identifier
- P240024
- Regulatory pathway
- Premarket approval application
- Applicant
- Nyxoah S.A.
- Product code
- MNQ
- Decision code
- APPR
- Decision date
- Aug 8, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, hypoglossal nerve, implanted, apnea.
- Applicant
- Nyxoah S.A.
- Product code
- MNQ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240024 received
Application receipt date recorded by FDA.
P240024 · FDA decision
APPR
P240024/S001 · Related supplement
Genio System 2.1
P240024/S002 · Related supplement
Genio System 2.1
P240024/S003 · Related supplement
Genio System 2.1
P240024/S004 · Related supplement
Genio System 2.1
Timeline entries are records held by MedtechLedger for P240024. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240024
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Genio System 2.1P240024/S001 | Nyxoah S.A. | PMA supplement | Oct 3, 2025 | FDA |
Genio System 2.1P240024/S002 | Nyxoah S.A. | PMA supplement | Nov 6, 2025 | FDA |
Genio System 2.1P240024/S003 | Nyxoah S.A. | PMA supplement | Jun 8, 2026 | FDA |
Genio System 2.1P240024/S004 | Nyxoah S.A. | PMA supplement | Jul 30, 2026 | FDA |
Explore the linked device profile
Other records with product code MNQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Model 4063 Dedicated Tray SealerP130008/S148 | Inspire Medical Systems | PMA supplement | Nov 5, 2026 | FDA |
INSPIRE II UPPER AIRWAY STIMULATORP130008/S144 | Inspire Medical Systems | PMA supplement | Oct 26, 2026 | FDA |
Model 3150 IPGP130008/S147 | Inspire Medical Systems | PMA supplement | Oct 22, 2026 | FDA |
Model 3150 IPGP130008/S146 | Inspire Medical Systems | PMA supplement | Oct 13, 2026 | FDA |
INSPIRE II UPPER AIRWAY STIMULATORP130008/S123 | Inspire Medical Systems | PMA supplement | Aug 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Nyxoah S.A.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Rue Edouard Belin, 12, Mont-Saint-Guibert, 1435
Sources and methodology
- Original FDA record: P240024
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





